Formulações de anestésicos locais de liberação controlada: aplicações terapêuticas
Drug-delivery systems for local anesthetics: therapeutic applications
Daniele Ribeiro de Araújo; Luciana de Matos Alves Pinto; Angélica de Fátima de Assunção Braga; Eneida de Paula
Resumo
Palavras-chave
Abstract
Keywords
References
Siddall PJ, Cousins MJ. Pain mechanisms and management: an update. Clin Exp Pharmacol Physiol. 1995;22:679-688.
Bennett G, Deer T, Stuart DP. Future directions in the management of pain by intraspinal drug delivery. J Pain Symp Manag. 2000;20:44-50.
Åkerman B, Arweström E, Post C. Local anesthetics potentiate spinal morphine antinociception. Anesth Analg. 1988;67:943-948.
Whiteside JB, Wildsmith JAW. Developments in local anesthetics drugs. Br J Anaesth. 2001;87:27-35.
de Jong RH. Local Anesthetics. 1994:87-88.
Kuzma PJ, Kline MD, Calkins MD. Progress in the development of ultra-long-acting local anesthetics. Reg Anesth. 1997;22:543-551.
Ranade VV. Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J Clin Pharmacol. 1989;29:685-694.
Lichtenberg D, Barenholz Y. Liposomes: Preparation, characterization and preservation. Method Biochem Anal. 1988;33:337-462.
Grant GJ, Bansinath M. Liposomal delivery systems for local anesthetics. Reg Anesth Pain Med. 2001;26:61-63.
Sharata HH, Katz KH. Liposomes. Int J Dermatol. 1996;35:761-769.
Malinovsky J-M, Benhamou D, Alafandy M. Neurotoxicological assessment after intracisternal injection of liposomal bupivacaine in rabbits. Anesth Analg. 1997;85:1331-1336.
Rongen HAH, Bult A, van Bennekom WP. Liposomes and immunoassays. J Immunol Meth. 1997;204:105-133.
Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery corneal penetration and absorption. J Control Release. 2000;63:135-140.
Kotwani RN, Gokhale PC, Bodhe PV. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm. 2002;238:11-15.
Erridge C, Stewart J, Bennet-Guerrero . The biological activity of a liposomal complete core lipopolysacharide vaccine. J Endotoxin Res. 2002;8:39-46.
Stuart DD, Kao GY, Allen T. A novel long-circulating and functional liposomal formulation of antisense oligonucleotides targeted against MDR1. Cancer Gene Therapy. 2000;7:466-475.
Boogaerts J, Declercq A, Lafont N. Toxicity of bupivacaine encapsulated into liposomes and injected intravenously: comparision with plain solutions. Anesth Analg. 1993;76:553-555.
Boogaerts JG, Lafont ND, Luo HC. Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits. Can J Anaesth. 1993;40:1201-1204.
Yu H-Y, Sun P, Hou W-Y. Prolonged local anesthetic effect of bupivacaine liposomes in rats. Int J Pharm. 1998;176:133-136.
Malinovsky JM, Bernard JM, Baudriment M. A chronic model for experimental investigation of epidural anesthesia in the rabbit. Reg Anesth. 1997;22:80-85.
Malinovsky JM, Le Corre P, Meunier JF. A dose-response study of liposomal bupivacaine in rabbits. J Contr Rel. 1999;60:111-119.
Boogaerts JG, Lafont ND, Declerq AG. Epidural administration of liposome-associated bupivacaine for the management of postsurgical pain: a first study. J Clin Anesth. 1994;6:315-320.
Lafont ND, Legros FJ, Boogaerts JG. Use of liposome-associated bupivacaine in a cancer pain syndrome. Anaesthesia. 1996;51:578-579.
Simonetti MPB, Andrade MP. Anestésicos locais e opióides encapsulados em lipossomas: um avanço farmacológico em progresso. Rev. Bras. Anestesiol. 1996;46:35-42.
Langerman L, Grant GJ, Zakowski M. Prolongation of epidural anesthesia using a lipid carrier with procaine, lidocaine and tetracaine. Anesth Analg. 1992;75:900-905.
Mowat JJ, Mok MJ, MacLeod BA. Liposomal bupivacaine. Anesthesiol. 1996;85:635-643.
Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm. 2001;225:15-30.
Matioli G. Ciclodextrinas e suas aplicações em alimentos, fármacos, agricultura, biotecnologia, química analítica e produtos gerais. 2000:3-5.
McCormack B, Gregoriadis G. Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo. Int J Pharmac. 1998;162:59-69.
Bibby D, Davies NM, Tucker IG. Mechanisms by wich cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharmac. 2000;197:1-11.
Kalinkova GN. Studies of beneficial interactions between active medicaments and excipients in pharmaceutical formulations. Int J Pharm. 1999;187:1-15.
Frömming K-H, Szejtli J. Topics in Inclusion Science: Cyclodextrins in Pharmacy. 1994:50-51.
Kirchmeier MJ, Ishida T, Chevrette J. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Liposome Res. 2001;11:15-29.
Veiga F, Fernandes C, Teixeira F. Oral availability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int J Pharm. 2000;202:165-171.
Dalmora ME, Dalmora SL, Oliveira AG. Inclusion complex of piroxicam withbeta-cyclodextrin and incorporation in cationic microemulsion: In vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharm. 2001;222:45-55.
Irie T, Uekama K. Pharmaceutical applications of ciclodextrins.: III.Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147-162.
Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins: 2.In vivo Drug delivery. J Pharm Sci. 1996;85:1142-1169.
Dollo G, Le Corre P, Chevanne F. Inclusion complexation of amide-type local anesthetics with beta-cyclodextrin and derivates: I.Physicochemical characterization. Int J Pharmac. 1996;131:219-228.
Dollo G, Le Corre P, Chevanne F. Inclusion complexation of amide-type local anesthetics with beta-cyclodextrin and derivates: Evaluation of affinity constants and in vitro transfer rate constants. Int J Pharmac. 1996;136:165-174.
Fréville JC, Dollo G, Le Corre P. Controlled systemic absorption and increased anesthetic effect of bupivacaine following epidural administration of bupivacaine-hydroxypropyl-beta-cyclodextrin complex. Pharm Res. 1996;13:1576-1580.
Dollo G, Thompson DO, Le Corre P. Inclusion complexation of amide-type local anesthetics with beta-cyclodextrin and derivates: III. Biopharmaceutics of bupivacaine-SBE7-beta-ciclodextrina complex following percutaneous sciatic nerve administration in rabbits. Int J Pharmac. 1998;164:11-19.
Dollo G, Le Corre P, Freville JC. Biopharmaceutics of local anesthetic cyclodextrin complexes following loco-regional administration. Ann Pharm Fr. 2000;58:425-432.
Fletcher D, Le Corre P, Guilbaud G. Antinociceptive effect of bupivacaine encapsulated in poly(D,L)-lactide-co-glycolide microspheres in the acute inflammatory pain model of carrageenin-injected rats. Anesth Analg. 1997;84:90-94.
Garry MG, Jackson DL, Geier HE. Evaluation of the efficacy of a bupivacaine polymer system on nociception and inflammatory mediator release. Pain. 1999;82:49-55.
Kohane DS, Lipp M, Kinney RC. Sciatic nerve blockade with lipid-protein-sugar particles containing bupivacaine. Pharm Res. 2000;17:1243-1249.
Grant GJ, Barenholz Y, Piskoun B. DRV liposomal bupivacaine: preparation, characterization and in vivo evaluation in mice. Pharm Res. 2001;18:336-343.